Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates
Oliver Kepp, Guido Kroemer
Abstract
HER3-DXd and T-DXd are antibody-drug conjugates (ADCs) that induce immunogenic cell death and bystander killing, enhancing antitumor immunity beyond target-specific cytotoxicity. These findings highlight novel mechanisms that can overcome antigen heterogeneity and suggest opportunities for improving ADC design and therapeutic synergy through informed combination with immunotherapies.
Topics & Concepts
Bystander effectDrugAntibodyAntibody-drug conjugateMedicineProgrammed cell deathImmunologyCancer researchMonoclonal antibodyApoptosisBiologyPharmacologyBiochemistryCAR-T cell therapy researchImmunotherapy and Immune ResponsesHER2/EGFR in Cancer Research